ExpreS2ion Biotech Holding AB (publ) (STO:EXPRS2)

Market Cap	51.47M
Revenue (ttm)	7.83M
Net Income (ttm)	-36.42M
Shares Out	2.66M
EPS (ttm)	-21.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,239
Average Volume	5,122
Open	19.78
Previous Close	19.88
Day's Range	18.70 - 19.78
52-Week Range	17.00 - 93.83
Beta	2.71
RSI	39.51
Earnings Date	May 1, 2025

About STO:EXPRS2

ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2ion Biotechnologies ApS, researches and develops preventive and therapeutic vaccine products in the Nordics and internationally. The company’s lead asset is ES2B-C001, a therapeutic vaccine for breast cancer that targets the human epidermal growth factor receptor 2 receptor. It is also developing ES2B-I002, a cytomegalovirus vaccine candidate to treat infectious diseases. In addition, the company out licenses its ExpreS2 platform to research institutes and pharmaceutical compa...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 20
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: EXPRS2

Financial Performance

In 2024, STO:EXPRS2's revenue was 7.83 million, a decrease of -11.07% compared to the previous year's 8.80 million. Losses were -36.42 million, -60.16% less than in 2023.